#1 Clinical Trials Search in Europe

Canakinumab

Canakinumab is an innovative drug being studied in clinical trials for its potential to treat various inflammatory conditions. This article explores the use of canakinumab in clinical trials for diseases such as systemic juvenile idiopathic arthritis, gout, Behçet’s disease, and myelofibrosis. We’ll examine how this interleukin-1 beta inhibitor is being tested for its efficacy and safety in managing these complex disorders.

Table of Contents

What is Canakinumab?

Canakinumab is a medication that belongs to a class of drugs known as monoclonal antibodies. It is also known by the brand name Ilaris[1]. This drug is designed to target and block a specific protein in the body called interleukin-1 beta (IL-1β), which plays a crucial role in inflammation[2].

How Does Canakinumab Work?

Canakinumab works by binding to and neutralizing IL-1β, a protein that promotes inflammation in the body. By blocking this protein, canakinumab helps reduce inflammation and its associated symptoms in various conditions[2]. This mechanism of action makes it particularly useful in treating diseases characterized by excessive inflammation.

Conditions Treated with Canakinumab

Canakinumab has been studied and used to treat several inflammatory conditions, including:

  • Cryopyrin-Associated Periodic Syndromes (CAPS): A group of rare genetic disorders characterized by recurrent episodes of fever and inflammation[2].
  • Systemic Juvenile Idiopathic Arthritis (SJIA): A form of arthritis in children that affects the entire body[1].
  • Schnitzler Syndrome: A rare disorder causing chronic hives, fever, and bone pain[3].
  • Behçet’s Disease: A disorder causing inflammation in blood vessels throughout the body[4].
  • Gout: A form of arthritis characterized by sudden, severe attacks of pain and swelling in joints[5].
  • Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) syndrome: A childhood condition causing recurring fevers and other symptoms[6].

How is Canakinumab Administered?

Canakinumab is typically administered as a subcutaneous injection, which means it’s injected under the skin. The dosage and frequency of administration can vary depending on the condition being treated and the patient’s response to the medication. For example:

  • For CAPS, it may be given every 8 weeks[2].
  • For SJIA, it might be administered every 4 weeks[1].
  • In some studies for gout, it was given as a single dose[5].

The exact dosage and schedule should always be determined by a healthcare provider based on the individual patient’s needs and condition.

Efficacy of Canakinumab

Clinical trials have shown promising results for canakinumab in treating various inflammatory conditions:

  • In CAPS patients, it has been shown to rapidly reduce symptoms and normalize inflammatory markers[2].
  • For SJIA, studies have demonstrated its effectiveness in reducing disease activity and allowing for the tapering of corticosteroids[1].
  • In Schnitzler Syndrome, canakinumab has shown to induce rapid and sustained remission of symptoms[3].
  • For gout, it has been effective in reducing pain intensity during acute flares[5].

Potential Side Effects

While canakinumab can be effective, it’s important to be aware of potential side effects. Common side effects may include:

  • Increased risk of infections, as the medication affects the immune system[2].
  • Injection site reactions, such as pain or redness at the injection site[2].
  • Headache, nausea, or abdominal pain[4].

It’s crucial to discuss all potential risks and benefits with your healthcare provider before starting treatment with canakinumab.

Ongoing Research

Researchers continue to explore the potential of canakinumab in treating other conditions. Some areas of ongoing research include:

  • Its use in treating vascular inflammation in patients with coronary artery disease[7].
  • Its potential in managing cytokine release syndrome in COVID-19 patients with pneumonia[8].
  • Its effectiveness in treating diabetic retinopathy, a complication of diabetes affecting the eyes[9].

These ongoing studies may lead to new applications for canakinumab in the future, potentially benefiting more patients with inflammatory conditions.

Condition Trial Description Key Outcomes Measured
Systemic Juvenile Idiopathic Arthritis (SJIA) Open-label, multi-arm study evaluating long-term safety and efficacy of canakinumab in SJIA patients Safety, tolerability, retention rate, ACR response, corticosteroid tapering, time to treatment failure
Gout Adaptive dose-ranging trial to determine target dose for acute flare management in refractory gout patients Pain intensity reduction, patient/physician global assessments, inflammatory markers (CRP, SAA)
Behçet’s Disease Open-label study evaluating canakinumab in Behçet’s disease patients with neurologic or vascular involvement Resolution of acute exacerbations, neurological scores, inflammatory markers, quality of life measures
PFAPA Syndrome Single-arm open-label pilot study of canakinumab in pediatric PFAPA patients Reduction in PFAPA flares, time to flare, quality of life assessment
Schnitzler Syndrome Open-label studies evaluating efficacy and safety of canakinumab in Schnitzler syndrome patients Clinical remission, prevention of disease relapse, changes in inflammatory markers, quality of life
Myelofibrosis Phase 2 study of canakinumab in patients with primary or post-ET/PV myelofibrosis Response based on IWG-MRT criteria, adverse events, spleen volume changes, overall survival, progression-free survival

FAQ

  • What is canakinumab? Canakinumab is a human monoclonal antibody that targets and neutralizes interleukin-1 beta, a pro-inflammatory cytokine. It is being studied as a treatment for various inflammatory conditions.
  • What conditions is canakinumab being tested for in clinical trials? Clinical trials are exploring canakinumab's potential in treating systemic juvenile idiopathic arthritis (SJIA), gout, Behçet's disease, periodic fever syndromes like PFAPA, Schnitzler syndrome, and myelofibrosis.
  • How is canakinumab administered? Canakinumab is typically administered as a subcutaneous injection. The dosage and frequency can vary depending on the condition being treated and the specific trial protocol.
  • What are some potential benefits of canakinumab treatment? Potential benefits include reduction in disease flares, improvement in symptoms, reduction in inflammation markers, and potentially improved quality of life for patients with inflammatory conditions.
  • Are there any side effects associated with canakinumab? While specific side effects can vary, clinical trials monitor for adverse events such as infections, injection site reactions, and other safety concerns. The trials aim to establish the overall safety profile of canakinumab for each condition.

Ongoing Clinical Trials on Canakinumab

  • Study on Canakinumab for Patients with PAPA Syndrome

    Not recruiting

    3 1 1
    Investigated drugs:
    Italy

  • Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Hungary Italy +2

  • Study on the Effectiveness and Safety of Pembrolizumab, Canakinumab, and Chemotherapy for Untreated Advanced Non-Small Cell Lung Cancer Patients

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

  • Study on Canakinumab for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes or MDS/MPN

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Interleukin-1 beta (IL-1β): A pro-inflammatory cytokine that plays a key role in various inflammatory processes in the body. Canakinumab targets and neutralizes this protein.
  • Systemic Juvenile Idiopathic Arthritis (SJIA): A form of arthritis in children that affects the entire body, causing fever, rash, and joint inflammation.
  • Gout: A type of arthritis caused by the buildup of uric acid crystals in joints, leading to sudden, severe attacks of pain, swelling, and redness.
  • Behçet's Disease: A rare disorder causing inflammation in blood vessels throughout the body, leading to various symptoms including mouth sores, eye inflammation, and skin problems.
  • Myelofibrosis: A rare type of blood cancer where the bone marrow is replaced by scar tissue, affecting normal blood cell production.
  • PFAPA Syndrome: Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis syndrome, a periodic fever condition primarily affecting children.
  • Schnitzler Syndrome: A rare inflammatory disorder characterized by chronic urticaria, fever, bone pain, and other symptoms.
  • C-reactive protein (CRP): A protein produced by the liver in response to inflammation, often used as a marker of inflammation in the body.
  • Erythrocyte Sedimentation Rate (ESR): A blood test that measures how quickly red blood cells settle in a test tube, used as a non-specific indicator of inflammation.
  • Serum Amyloid A (SAA): An acute-phase protein produced in response to inflammation, often used as a marker in clinical trials.
  • Visual Analog Scale (VAS): A measurement tool used to assess subjective characteristics or attitudes that cannot be directly measured, often used for pain assessment.
  • Subcutaneous (SC) injection: An injection administered into the fatty tissue layer between the skin and muscle.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Used in the treatment of various diseases.

References

  1. https://clinicaltrials.gov/study/NCT01676948
  2. https://clinicaltrials.gov/study/NCT01245127
  3. https://clinicaltrials.gov/study/NCT01276522
  4. https://clinicaltrials.gov/study/NCT02756650
  5. https://clinicaltrials.gov/study/NCT00798369
  6. https://clinicaltrials.gov/study/NCT02775994
  7. https://clinicaltrials.gov/study/NCT06691217
  8. https://clinicaltrials.gov/study/NCT04476706
  9. https://clinicaltrials.gov/study/NCT01589029